Cyclacel Pharmaceuticals, Inc. Announces Presentation of Preclinical Data Demonstrating Combination Potential of Clinical Agents at American Association for Cancer Research Annual Meeting

BERKELEY HEIGHTS, N.J., April 4, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced the presentation of preclinical results for two of its clinical compounds at the 102nd Annual Meeting of the American Association of Cancer Research (AACR) in Orlando, Florida.